Key result
Circulating extracellular vesicles show promise as noninvasive biomarkers and drug delivery vehicles in cardiovascular disease.
Why the study?
Early detection and management of cardiovascular diseases reduce premature morbidity and mortality, generating interest in circulating extracellular vesicles as biomarkers and drug delivery vehicles.
Do circulating extracellular vesicles serve as effective biomarkers and drug delivery vehicles in cardiovascular diseases?
Do circulating extracellular vesicles serve as effective biomarkers and drug delivery vehicles in cardiovascular diseases?
This review highlights the diagnostic, prognostic, and therapeutic potential of circulating extracellular vesicles in cardiovascular medicine, underscoring the need for standardized methods to translate these findings into clinical practice.
Answers are grounded in this paper and cite their sources.
Supports exploratory biomarker research in cardiovascular disease; leaves open clinical adoption pending standardized validation.
Extracellular vesicles (EVs) are composed of a lipid bilayer containing transmembrane and soluble proteins. Subtypes of EVs include ectosomes (microparticles/microvesicles), exosomes, and apoptotic bodies that can be released by various tissues into biological fluids. EV cargo can modulate physiological and pathological processes in recipient cells through near- and long-distance intercellular communication. Recent studies have shown that origin, amount, and internal cargos (nucleic acids, proteins, and lipids) of EVs are variable under different pathological conditions, including cardiovascular diseases (CVD). The early detection and management of CVD reduce premature morbidity and mortality. Circulating EVs have attracted great interest as a potential biomarker for diagnostics and follow-up of CVD. This review highlights the role of circulating EVs as biomarkers for diagnosis, prognosis, and therapeutic follow-up of CVD, and also for drug delivery. Despite the great potential of EVs as a tool to study the pathophysiology of CVD, further studies are needed to increase the spectrum of EV-associated applications.
No takes yet. Share an insight, caveat, or question.
Freitas et al. (2021) conducted a review in Cardiovascular Diseases (CVD). Circulating Extracellular Vesicles (EVs) was evaluated. Circulating extracellular vesicles hold significant potential as non-invasive biomarkers for the diagnosis, prognosis, and therapeutic monitoring of cardiovascular diseases, and show promise as drug delivery vehicles.
Synapse has enriched 10 related papers. Consider them for comparative context: